Combination antithymocyte globulin and soluble TNFα inhibitor (etanercept) +/− mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Bone Marrow Transplantation

• Publication date

  2006-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.bmt.1705380PMID 16699531
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Graft-versus-host disease

  2007cited by this paper
• Thomas' Hematopoietic Cell Transplantation (3rd edn)

  2005cited by this paper
• Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept

  2005cited by this paper
• Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.

  2005cited by this paper
• Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease

  2005cited by this paper
• Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease.

  2005cited by this paper
• Improved survival in steroid‐refractory acute graft versus host disease after non‐myeloablative allogeneic transplantation using a daclizumab‐based strategy with comprehensive infection prophylaxis

  2004cited by this paper
• Infliximab treatment for steroid-refractory acute graft-versus-host disease.

  2004cited by this paper
• Polymorphisms within the genes encoding TNF-alpha and TNF-beta associate with the incidence of post-transplant complications in recipients of allogeneic hematopoietic stem cell transplants.

  2004cited by this paper
• Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.

  2004cited by this paper
• Infliximab for the Treatment of Severe Steroid Refractory Acute Graft-versus-host Disease in Three Patients after Allogeneic Hematopoietic Transplantation

  2003cited by this paper
• Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study.

  2003cited by this paper
• Infliximab for steroid‐refractory acute GVHD: A case series

  2003cited by this paper
• Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation

  2002cited by this paper
• Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease.

  2002cited by this paper
• Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience.

  2001cited by this paper
• Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody

  2001cited by this paper
• Treatment of steroid refractory acute and chronic graft‐versus‐host disease with daclizumab

  2001cited by this paper
• Combination therapy with tacrolimus and anti‐thymocyte globulin for the treatment of steroid‐resistant acute graft‐versus‐host disease developing during cyclosporine prophylaxis

  2001cited by this paper
• Etanercept in graft-versus-host disease

  2000cited by this paper
• Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.

  1995cited by this paper
• Graft-versus-host disease.

  1991cited by this paper
• CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S

  1974cited by this paper

• Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.

  2025cites this paper
• A New Strategy in Transplantation: Tipping the Balance in the Tussle Between Graft-versus-host Disease and the Graft-versus-leukemia Effect

  2024cites this paper
• One-way donor-to-recipient human leukocyte antigen mismatch and graft-versus-host disease in liver transplantation: an observational study of a single-center experience in Korea

  2023cites this paper
• Treatment of steroid-refractory graft versus host disease in children

  2023cites this paper
• Impaired Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation: Its Pathogenesis and Potential Treatments

  2021cites this paper
• Lyell-Like Acute Graft-Versus-Host-Disease

  2021cites this paper
• Tumor Necrosis Factor Inhibitors

  2021cites this paper
• Treatment and unmet needs in steroid-refractory acute graft-versus-host disease

  2020cites this paper
• A Limited Sampling Strategy for Therapeutic Drug Monitoring of Mycophenolate Mofetil for Prophylaxis of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation

  2020cites this paper
• Etanercept as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients.

  2019cites this paper
• Blockade of TNFα to Improve Human CD34+ Cell Repopulating Activity in Allogeneic Stem Cell Transplantation

  2019cites this paper
• Cytokines in GVHD and GVL

  2019cites this paper
• Effects on tumor immunity, liver, gut, lung and survival after cutaneous graft-versus-host disease regulated by photochemotherapy

  2018cites this paper
• Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit

  2018cites this paper
• Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis

  2018cites this paper
• 我如何治疗造血干细胞移植后急性移植物抗宿主病

  2017cites this paper
• [How I treat acute graft versus host disease].

  2017cites this paper
• Cytokines in Hematopoietic Stem Cell Transplantation

  2017cites this paper
• Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease

  2017cites this paper
• Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience

  2017cites this paper
• Pharmacokinetics and immunological outcomes of alemtuzumab-based treatment for steroid-refractory acute GvHD

  2016cites this paper
• Graft Versus Host Disease After Liver Transplantation in Adults: A Case series, Review of Literature, and an Approach to Management

  2016cites this paper
• Acute cutaneous graft‐versus‐host disease resembling type II (atypical adult) pityriasis rubra pilaris

  2015cites this paper
• Understanding graft-versus-host disease. Preliminary findings regarding the effects of exercise in affected patients.

  2015cites this paper
• ADVANCES IN HEMATOPOIETIC CELL TRANSPLANTATION The biology of graft-versus-host disease: experimental systems instructing clinical practice

  2014cites this paper
• Immunologic Outcomes of Allogeneic Stem Cell Transplantation: Graft-Versus-Host and Graft-Versus-Leukemia Responses and Implications for Future Therapy

  2014cites this paper
• Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.

  2014cites this paper
• The biology of graft-versus-host disease: experimental systems instructing clinical practice.

  2014cites this paper
• Documentation of off-label use of biologics in Rheumatoid Arthritis

  2013cites this paper
• Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC).

  2013cites this paper
• Cytokines in Graft-versus-host Disease and Graft-versus-leukemia

  2013cites this paper
• Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.

  2013cites this paper
• First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

  2012cites this paper
• Transplant-Associated Thrombotic Microangiopathy in Childhood

  2012cites this paper
• Secondary treatment of acute graft-versus-host disease: a critical review.

  2012cites this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

  2011cites this paper
• Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation

  2011cites this paper
• Alemtuzumab as salvage therapy for steroid and ATG/etanercept-refractory acute GVHD

  2011cites this paper
• Monoclonal antibodies to treat graft-versus-host disease.

  2011cites this paper
• Clinical and epidemiological research

  2011cites this paper
• Graft-versus-host disease

  2010cites this paper
• Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins

  2010cites this paper
• Disseminated Rhizopus microsporus infection cured by salvage allogeneic hematopoietic stem cell transplantation, antifungal combination therapy, and surgical resection

  2010cites this paper
• Glucocorticoid-refractory acute graft-versus-host disease.

  2010cites this paper
• Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange

  2010cites this paper
• Soluble lymphotoxin is an important effector molecule in GVHD and GVL.

  2010cites this paper
• Manifestations and Treatment of Acute Graft‐versus‐Host Disease

  2009cites this paper
• Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease

  2009cites this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

  2009cites this paper
• Unrelated donor haematopoietic stem cell transplantation for adult patients with haematological malignancies.

  2009cites this paper
• Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease.

  2009cites this paper
• Acute graft‐versus‐host disease after liver transplant: Novel use of etanercept and the role of tumor necrosis factor α inhibitors

  2009cites this paper
• Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Segunda parte: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab

  2008cites this paper
• 2008for the treatment of rheumatic diseases, Updated consensus statement on biological

  2008cites this paper
• Current and future approaches for control of graft-versus-host disease

  2008cites this paper
• Current and novel therapies in acute GVHD.

  2008cites this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

  2008cites this paper
• Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation

  2008cites this paper
• [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab].

  2008cites this paper
• Impact of cytokine gene polymorphisms on graft-vs-host disease.

  2008cites this paper
• Novel drugs for the prevention and treatment of acute GVHD.

  2008cites this paper
• Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?

  2007cites this paper
• Advancesintheunderstandingofacutegraft-versus-hostdisease

  2007cites this paper
• Advances in the understanding of acute graft‐versus‐host disease

  2007cites this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

  2007cites this paper
• Treatment of Autoimmune Disease with Rabbit Anti‐T Lymphocyte Globulin

  2007cites this paper
• ANÁLISIS DE COSTES DEL TRASPLANTE HEMATOPOYÉTICO ALOGÉNICO CON TÉCNICAS DE REDUCCIÓN LEUCOCITARIA EN PEDIATRÍA

  2007cites this paper